Bora Appoints First Division President of its CDMO Business
Bora Pharmaceuticals Co., Ltd. recently announced the appointment of J.D. Mowery to the newly created position of Division President of Bora’s CDMO business.
“Through our acquisitions and joint venture with Tanvex we have added four U.S. sites to our network this year, and the global scale of our CDMO business requires dedicated leadership to support its future growth,” said Bobby Sheng, Group Chairman and CEO of Bora. “I am thrilled to welcome J.D., who brings nearly 25 years’ experience in the CDMO and biopharmaceutical industries, and I look forward to working with him to meet the needs of our customers, and of this rapidly growing organization.”
Mowery joins Bora Group from KBI Biopharma a JSR Life Sciences company, where he served as President and CEO and led global CDMO operations. He serves as a board member of AST, a technology leader specializing in advanced aseptic filling and closing systems, and was previously an Officer of JSR Corporation. J.D. has also held roles of increasing responsibility at innovators such as Genentech, Treadwell Therapeutics, Juno Therapeutics, Celgene, and executive-level roles with CDMOs including Lonza and AGC Biologics. His extensive experience includes operations, manufacturing, tech transfer, facility construction, business development, and investor relations, across North America, Europe, and Asia. Mowery holds a bachelor’s from George Fox University and an MBA from Marylhurst University.
Founded in 2007, Bora Pharmaceutical Co., Ltd. is the largest pharmaceutical manufacturer in Taiwan with well-connected global distribution to supply more than 100 countries around the world. Bora is dedicated to becoming a global leader in pharmaceutical manufacturing by offering its clients the best quality, efficiency, and reliability. For more information, visit www.bora-corp.com.
Total Page Views: 342
